UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2016
XENON PHARMACEUTICALS INC.
(Exact name of Registrant as Specified in Its Charter)
|
Canada |
001-36687 |
98-0661854 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
200-3650 Gilmore Way
Burnaby, British Columbia V5G 4W8
Canada
(Address of principal executive offices including zip code)
(604) 484-3300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Item 8.01 |
Other Events |
On March 9, 2016, Xenon Pharmaceuticals Inc. (the “Company”) announced the meeting and record date and certain other information relating to its 2016 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.
A copy of the filing submitted to SEDAR is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
SEDAR filing submitted March 9, 2016. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Xenon Pharmaceuticals Inc. |
|
|
|
|
|
|
|
Date: March 9, 2016 |
|
By: |
/s/ Ian Mortimer |
|
|
|
|
Ian Mortimer |
|
|
|
|
Chief Financial Officer& Chief Operating Officer |
EXHIBIT INDEX
|
Exhibit Number |
Description |
|
99.1 |
SEDAR filing submitted March 9, 2016. |
EXHIBIT 99.1
|
|
Joshua P. McGinn, CEP Senior Vice President, Western Region Relationship Management
American Stock Transfer & Trust Company, LLC One Embarcadero Center – Suite 566 San Francisco, CA 94111 Office: 415.835-1313 |
March 9, 2016
|
|
|
|
Alberta Securities Commission |
|
|
British Columbia Securities Commission |
|
|
Ontario Securities Commission |
|
|
|
|
RE: Xenon Pharmaceuticals Inc.
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:
|
Date of meeting: |
June 2, 2016 |
|
Record date for notice: |
April 4, 2016 |
|
Record date for voting: |
April 4, 2016 |
|
Beneficial ownership determination date: |
April 4, 2016 |
|
Securities entitled to notice: |
Common Shares |
|
Securities entitled to vote: |
Common Shares |
|
Issuer mailing directly to non objecting beneficial owners: |
No |
|
Issuer will pay for objecting beneficial owner material distribution: |
Yes |
|
Issuer using notice-and-access for registered investors: |
No |
|
Issuer using notice-and-access for non-registered investors: |
No |
|
Notice-and-access stratification criteria: |
N/A |
Yours very truly,
/s/ Joshua P. McGinn
Joshua P. McGinn
Senior Vice-President, Western Region
Relationship Management